4564.T stock OncoTherapy JPX JPY 22.00 on 19 Mar 2026: heavy volume drives intraday focus

4564.T stock is trading at JPY 22.00 intraday on the JPX on 19 Mar 2026 after a one-day fall of -4.35% on heavy volume. Traders have exchanged 53,956,400.00 shares today, more than twice the average, making OncoTherapy Science, Inc. one of the most active names on the board. The move tracks mixed clinical progress, a tight cash buffer per share, and technical indicators showing short-term momentum. This intraday note gives price, volume, valuation and a concise outlook for intraday traders and longer-term investors.

Intraday movers: 4564.T stock price and volume action

The main fact: OncoTherapy Science, Inc. (4564.T) is at JPY 22.00, down -1.00 or -4.35% from the previous close. Volume is 53,956,400.00 today versus average volume 40,524,089.00, a relative volume of 2.14, signalling outsized intraday activity. One clear driver for the active trading is position adjustments ahead of the company’s next earnings announcement on 2026-05-11.

Fundamentals and valuation for 4564.T stock

OncoTherapy reports EPS of -2.83 and a trailing PE of -8.13, reflecting net losses typical for clinical-stage biotech. Key ratios show price-to-book 3.88 and price-to-sales 10.08, with cash per share at 6.06 and a strong current ratio of 8.51. These figures indicate a capital-heavy R&D profile with solid short-term liquidity but limited profitability. Investors should weigh the high R&D intensity (R&D/revenue 65.79%) against uncertain near-term revenue growth.

Technical setup and intraday signals for 4564.T stock

Technicals show short-term strength but mixed trend cues. The 50-day average is 21.22 and the 200-day average is 23.90. RSI sits at 64.18, MACD histogram is positive at 0.24, and Bollinger upper band is 23.54, suggesting resistance near JPY 23.54 and support near JPY 19.26. Traders should watch intraday range JPY 22.00–23.00 and use ATR 1.35 for stop placement.

Meyka AI grade, forecast and price targets for 4564.T stock

Meyka AI rates 4564.T with a score out of 100: 69.29, Grade B, suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of JPY 17.31, a monthly level of JPY 16.61, and a quarterly level of JPY 15.60. Versus the current price JPY 22.00, the model implies a near-term downside of -21.23% to the yearly forecast. Forecasts are model-based projections and not guarantees.

Clinical pipeline and news catalysts affecting 4564.T stock

OncoTherapy’s pipeline includes peptide vaccine S-588410 in Phase III and small molecules OTS167 and OTS964 in earlier trials. Clinical-readout timelines and regulatory steps are primary binary catalysts for valuation moves. Company disclosures and trial updates often create intraday spikes in liquidity as traders reprice event risk. For company details, see the corporate site source. For wider market context on biotech flows in Japan, monitor industry coverage from major outlets such as Nikkei source.

Trade considerations and risks for 4564.T stock

One clear risk is earnings volatility: trailing metrics show net losses and negative ROE of -63.03%, underlining clinical-stage risk. Balance-sheet strengths include cash per share 6.06 and low debt-to-equity 0.00, reducing immediate solvency risk. Liquidity is high today but can evaporate; use position sizing and set stops consistent with ATR 1.35. Consider event-driven strategies around trial readouts and the earnings date 2026-05-11.

Final Thoughts

Intraday, 4564.T stock is the most active biotech name on the JPX today, trading at JPY 22.00 on heavy volume 53,956,400.00. Short-term technicals show momentum but face resistance near JPY 23.54 and the 200-day average JPY 23.90. Fundamentals point to high R&D spending, EPS -2.83, and price-to-book 3.88, so the stock is sensitive to clinical news. Meyka AI’s forecast model projects a yearly price of JPY 17.31, implying an expected downside of -21.23% from the current price. Price targets for scenarios: conservative short-term target JPY 25.00 and bullish event-driven target JPY 35.00 (year high). These targets reflect technical resistance and the company’s clinical optionality. Use tight risk controls for intraday trades and monitor upcoming clinical updates and the earnings announcement on 2026-05-11. Meyka AI is an AI-powered market analysis platform providing data-driven context; forecasts are model-based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.